iCAD (ICAD) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 21, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	ICAD
Entity Registrant Name	ICAD INC
Entity Central Index Key	749,660
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Accelerated Filer
Entity Common Stock, Shares Outstanding		16,157,466
Entity Public Float			$ 70,242,336

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 8,585	$ 15,280
Trade accounts receivable, net of allowance for doubtful accounts of $172 in 2016 and $236 in 2015	5,189	7,488
Inventory, net	3,727	4,315
Prepaid expenses and other current assets	1,128	684
Assets held for sale	1,304
Total current assets	19,933	27,767
Property and equipment:
Equipment	7,180	7,049
Leasehold improvements	62	62
Furniture and fixtures	305	295
Marketing assets	376	376
Total property and equipment	7,923	7,782
Less accumulated depreciation and amortization	6,538	5,475
Net property and equipment	1,385	2,307
Other assets:
Other assets	53	94
Intangible assets, net of accumulated amortization of $7,518 in 2016 and $10,896 in 2015	3,183	4,274
Goodwill	14,097	14,198
Total other assets	17,333	18,566
Total assets	38,651	48,640
Current liabilities:
Accounts payable	1,577	1,593
Accrued expenses	4,988	4,220
Capital lease payable, short-term portion	86	969
Deferred revenue	5,372	7,497
Liabilities held for sale	832
Total current liabilities	12,855	14,279
Other long-term liabilities	83	29
Deferred revenue, long-term portion	668	1,079
Settlement costs, long-term portion		421
Capital lease - long-term portion	0	86
Deferred tax	7
Total liabilities	13,613	15,894
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $ .01 par value: authorized 1,000,000 shares; none issued.
Common stock, $ .01 par value: authorized 30,000,000 shares; issued 16,260,663 in 2016 and 15,923,349 in 2015; outstanding 16,074,832 in 2016 and 15,737,518 in 2015	163	159
Additional paid-in capital	213,899	211,512
Accumulated deficit	(187,609)	(177,510)
Treasury stock at cost, 185,831 shares in 2016 and 2015	(1,415)	(1,415)
Total stockholders' equity	25,038	32,746
Total liabilities and stockholders' equity	$ 38,651	$ 48,640

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts on trade accounts receivable	$ 172	$ 236
Intangible assets, accumulated amortization	$ 7,518	$ 10,896
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	16,260,663	15,923,349
Common stock, shares outstanding	16,074,832	15,737,518
Treasury stock, shares	185,831	185,831

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue:
Products	$ 10,471	$ 14,198	$ 18,683
Service and supplies	15,867	27,356	25,241
Total revenue	26,338	41,554	43,924
Cost of Revenue:
Products	918	3,130	4,912
Service and supplies	5,713	7,357	6,000
Amortization and depreciation	1,189	1,717	1,785
Total cost of revenue	7,820	12,204	12,697
Gross profit	18,518	29,350	31,227
Operating expenses:
Engineering and product development	9,518	9,163	8,159
Marketing and sales	10,179	12,404	12,468
General and administrative	7,675	8,788	8,044
Amortization and depreciation	1,116	1,631	1,741
Goodwill and long-lived asset impairment		27,443
Total operating expenses	28,488	59,429	30,412
Income (loss) from operations	(9,970)	(30,079)	815
Other (expense) income:
Interest expense	(63)	(650)	(2,640)
Gain from change in fair value of warrant liability			1,835
Loss from extinguishment of debt		(1,723)	(903)
Interest income	10	21	37
Other expense, net	(53)	(2,352)	(1,671)
Loss before income tax expense	(10,023)	(32,431)	(856)
Income tax expense	76	16	153
Net loss and comprehensive loss	$ (10,099)	$ (32,447)	$ (1,009)
Net loss per share:
Basic	$ (0.63)	$ (2.07)	$ (0.07)
Diluted	$ (0.63)	$ (2.07)	$ (0.07)
Weighted average number of shares used in computing loss per share:
Basic	15,932	15,686	14,096
Diluted	15,932	15,686	14,096

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]
Beginning Balance at Dec. 31, 2013	$ 21,377	$ 111	$ 166,735	$ (144,054)	$ (1,415)
Beginning Balance, shares at Dec. 31, 2013		11,084,119
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively	(111)	$ 1	(112)
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively,Shares		75,530
Issuance of common stock for warrants exercised	3,726	$ 4	3,722
Issuance of common stock for warrants exercised, shares		450,000
Issuance of stock for acquisitions	8,556	$ 12	8,544
Issuance of stock for acquisitions, shares		1,200,000
Issuance of common stock pursuant to stock option plans	$ 708	$ 1	707
Issuance of common stock pursuant to stock option plans, shares	162,528	162,528
Sale of common stock	$ 28,214	$ 28	28,186
Sale of common stock, shares		2,760,000
Stock-based compensation	1,318		1,318
Net loss	(1,009)			(1,009)
Ending Balance at Dec. 31, 2014	62,779	$ 157	209,100	(145,063)	(1,415)
Ending Balance, shares at Dec. 31, 2014		15,732,177
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively	(87)	$ 1	(88)
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively,Shares		111,700
Issuance of common stock pursuant to stock option plans	$ 366	$ 1	365
Issuance of common stock pursuant to stock option plans, shares	79,472	79,472
Stock-based compensation	$ 2,135		2,135
Net loss	(32,447)			(32,447)
Ending Balance at Dec. 31, 2015	32,746	$ 159	211,512	(177,510)	(1,415)
Ending Balance, shares at Dec. 31, 2015		15,923,349
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively	(114)	$ 3	(117)
Issuance of common stock relative to vesting of restricted stock, net of 9,904, 13,058 and 27,299 shares forfeited for tax obligations in 2014, 2015 and 2016 respectively,Shares		261,731
Issuance of common stock pursuant to stock option plans	$ 198	$ 1	197
Issuance of common stock pursuant to stock option plans, shares	75,583	75,583
Stock-based compensation	$ 2,307		2,307
Net loss	(10,099)			(10,099)
Ending Balance at Dec. 31, 2016	$ 25,038	$ 163	$ 213,899	$ (187,609)	$ (1,415)
Ending Balance, shares at Dec. 31, 2016		16,260,663

Consolidated Statements of Sha6

Consolidated Statements of Shareholders' Equity (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Shares forfeited for tax obligations	27,299	13,058	9,904
Common Stock [Member]
Shares forfeited for tax obligations	27,299	13,058	9,904
Additional Paid-in Capital [Member]
Shares forfeited for tax obligations	27,299	13,058	9,904

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flow from operating activities:
Net loss	$ (10,099,000)	$ (32,447,000)	$ (1,009,000)
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Amortization	983,000	1,768,000	2,270,000
Depreciation	1,322,000	1,580,000	1,256,000
Bad debt provision	177,000	383,000	167,000
Stock-based compensation expense	2,307,000	2,135,000	1,318,000
Amortization of debt discount and debt costs	(23,000)	341,000	1,246,000
Gain from acquisition settlement	(249,000)
Goodwill and long-lived asset impairment		27,443,000
Interest on settlement obligations	82,000	146,000	206,000
Deferred tax liability	7,000
Loss (gain) from change in fair value of warrant liability			(1,835,000)
Loss on disposal of assets	10,000	125,000
Loss on extinguishment of debt		1,723,000	903,000
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	2,201,000	1,772,000	(840,000)
Inventory	596,000	(1,987,000)	(323,000)
Prepaid and other assets	(504,000)	(197,000)	11,000
Accounts payable	(16,000)	(557,000)	150,000
Accrued expenses	309,000	(2,060,000)	296,000
Deferred revenue	(2,581,000)	(2,068,000)	(612,000)
Total adjustments	4,621,000	30,547,000	4,213,000
Net cash (used for) provided by operating activities	(5,478,000)	(1,900,000)	3,204,000
Cash flow from investing activities:
Additions to patents, technology and other	(12,000)	(40,000)	(50,000)
Additions to property and equipment	(337,000)	(932,000)	(1,214,000)
Net cash used for investing activities	(355,000)	(2,672,000)	(4,746,000)
Cash flow from financing activities:
Issuance of common stock for cash, net			28,214,000
Stock option exercises	198,000	366,000	708,000
Warrant exercise			1,575,000
Taxes paid related to restricted stock issuance	(114,000)	(87,000)	(110,000)
Principal payments of capital lease obligations	(946,000)	(1,397,000)	(655,000)
Principal repayment of debt financing, net		(11,250,000)	(7,850,000)
Net cash (used for) provided by financing activities	(862,000)	(12,368,000)	21,882,000
Increase (decrease) in cash and equivalents	(6,695,000)	(16,940,000)	20,340,000
Cash and equivalents, beginning of year	15,280,000	32,220,000	11,880,000
Cash and equivalents, end of year	8,585,000	15,280,000	32,220,000
Supplemental disclosure of cash flow information:
Interest paid	70,000	558,000	1,637,000
Taxes paid	67,000	128,000	157,000
Non-cash items from investing and financing activities:
Settlement of warrant liability with purchase of common stock			2,151,000
Issuance of common stock related to acquisition of Radion, Inc and DermEbx			8,556,000
VuComp M-Vu CAD [Member]
Cash flow from investing activities:
Acquisition	$ (6,000)
VuComp M-Vu Breast Density Product [Member]
Cash flow from investing activities:
Acquisition		$ (1,700,000)
DermEbx and Radion [Member]
Cash flow from investing activities:
Acquisition			$ (3,482,000)

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(1) Summary of Significant Accounting Policies (a) Nature of Operations and Use of Estimates iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft System which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs. The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s management believes that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth. The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts, and an operations, research, development, manufacturing and warehousing facility in San Jose, California. The Company operates in two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products, and the Therapy segment consists of radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 8 for segment, major customer and geographical information. The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities. (b) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation. (c) Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest (d) Financial instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2016 and 2015. (e) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2016 and 2015 is adequate. The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2016 (in thousands): 2016 2015 2014 Balance at beginning of period $ 236 $ 203 $ 73 Additions charged to costs and expenses 177 383 167 Reductions (241 ) (350 ) (37 ) Balance at end of period $ 172 $ 236 $ 203 (f) Inventory Inventory is valued at the lower of cost or market value, with cost determined by the first-in, first-out As of December 31, 2016 2015 Raw materials $ 2,503 $ 2,900 Work in process 75 154 Finished Goods 1,149 1,261 Inventory $ 3,727 $ 4,315 (g) Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 years Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5 (h) Long Lived Assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21, • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma In accordance with ASC 360-10-35-17, In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the Asset Group. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values, and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges. Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of VuComp, DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2016 and 2015 are as follows (in thousands): 2016 2015 Weighted Gross Carrying Amount Patents and licenses $ 583 $ 579 5 years Technology 9,567 14,075 10 years Customer relationships 292 268 7 years Tradename 259 248 10 years Total amortizable intangible assets 10,701 15,170 Accumulated Amortization Patents and licenses $ 477 $ 451 Technology 6,754 9,996 Customer relationships 28 201 Tradename 259 248 Total accumulated amortization 7,518 10,896 Total amortizable intangible assets, net $ 3,183 $ 4,274 Amortization expense related to intangible assets was approximately $983,000, $1,768,000 and $2,270,000 for the years ended December 31, 2016, 2015, and 2014, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2017 $ 574 2018 511 2019 499 2020 370 2021 311 Thereafter 918 $ 3,183 (i) Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles - Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company would record an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. As a result of external factors and general uncertainty related to reimbursement for non-melanoma The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships and trade-names. The allocation process was performed only for purposes of testing goodwill for impairment. The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results. The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit. The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million for the quarter ended June 30, 2015. The Company performed an annual impairment assessment at October 1, 2016 and compared the fair value of each reporting unit to its carrying value as of this date. Fair value was approximately 816% of carrying value for the Detection reporting unit and 126% of carrying value for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company determined the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company used internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 15% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborated the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weight the methodologies appropriately. In April 2015, the Company acquired VuComp’s M-Vu ® In January 2016, the Company completed the acquisition of VuComp’s M-Vu In December, 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. The Company will sell and convey to Buyer all right, title and interest to certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets. As a result of the agreement, the Company determined that it had assets held for sale as of December 31, 2016 and the sale constituted the sale of a business. As of December 31, 2016, the Company allocated $394,000 of goodwill to assets held for sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement. A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Balance at December 31, 2014 7,663 19,600 27,263 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (13,981 ) (40,809 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097 (j) Revenue Recognition The Company recognizes revenue primarily from the sale of products, services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, Multiple-Deliverable Revenue Arrangement 2009-13”) No. 2009-14, Certain Arrangements That Contain Software Elements 2009-14”) 985-605, “Software” 985-605”). Leases” The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “ Revenue Recognition 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, Services (k) Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house (l) Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2016, 2015 and 2014, were as follows (in thousands): 2016 2015 2014 Beginning accrual balance $ 19 $ 14 $ 25 Warranty provision 47 54 58 Usage (55 ) (49 ) (69 ) Ending accrual balance $ 11 $ 19 $ 14 The warranty accrual above includes long-term warranty obligations of $0, $2,000 and $5,000 for the years ended December 31, 2016, 2015 and 2014 respectively. (m) Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred. (n) Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2016, 2015 and 2014 was approximately $955,000, $950,000 and $882,000 respectively. (o) Net Loss per Common Share The Company follows FASB ASC 260-10, A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss available to common shareholders $ (10,099 ) $ (32,447 ) $ (1,009 ) Basic shares used in the calculation of earnings per share 15,932 15,686 14,096 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 15,932 15,686 14,096 Net loss per share : Basic $ (0.63 ) $ (2.07 ) $ (0.07 ) Diluted $ (0.63 ) $ (2.07 ) $ (0.07 ) The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2016 2015 2014 Common stock options 1,425,348 1,571,998 1,417,887 Restricted Stock 511,398 516,396 309,317 1,936,746 2,088,394 1,727,204 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested. (p) Income Taxes The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2016 and 2015, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes. ASC 740-10 740-10 de-recognition, (q) Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted. The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. The fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. The Company granted performance based restricted stock during 2016 based on achievement of certain revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of the performance objectives and compensation cost is re-measured Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations. (r) Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Fair value measurements using: (000’s) as of December 31, 2015 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 13,577 $ — $ — $ 13,577 Total Assets $ 13,577 $ — $ — $ 13,577 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. In 2015 the Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note (h) and Note (i) and re-measured (s) Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, 2014-09, 2016-08, 2016-10, No. 2014-09. 2014-09 one-year 2014-09 2014-09, In February 2016, the FASB issued ASU No. 2016-02, right-of-use off-balance In March 2016, the FASB issued ASU 2016-09, 2016-09 In August 2016, the FASB issued ASU 2016-15,

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisitions	(2) Acquisitions Acquisition of VuComp Cancer detection portfolio On January 13, 2016, the Company completed the acquisition of the VuCOMP cancer detection portfolio, including the M-Vu As noted below, the Company acquired VuComp’s M-Vu Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255 The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated amortizable life Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255 The assets obtained in the acquisition of VuComp’s M-Vu M-Vu Acquisition of VuComp M-Vu On April 29, 2015, pursuant to the terms of the Asset Purchase Agreement with VuComp, the Company purchased VuComp’s M-Vu Business Combinations The amount allocated to the acquired assets was estimated primarily through the use of discounted cash flow valuation techniques. Appraisal assumptions utilized under this method include a forecast of estimated future net cash flows, as well as discounting the future net cash flows to their present value. The acquired technology is being amortized over the estimated useful life of approximately eight years and nine months from the closing of the transaction. The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life (in thousands): Amount Estimated Amortizable Life Developed Technology $ 900 8 years 9 months Goodwill 800 Purchase price $ 1,700 The assets obtained in the acquisition of VuComp’s M-Vu

Assets and Liabilities Held for

Assets and Liabilities Held for Sale	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Held for Sale	(3) Assets and Liabilities Held for Sale In December, 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. In accordance with the agreement, the Company sold to Invivo all right, title and interest to certain intellectual property relating to the Company’s VersaVue Software and DynaCAD product and related assets for $3.2 million. The Company closed the transaction in January 2017 less a holdback reserve of $350,000 for a net of approximately $2.9 million. In accordance with ASC 360-10-35-43, In addition the Company determined the sale constituted the sale of a business in accordance with ASC 805. In connection with the transaction, the Company allocated $394,000 of goodwill to assets held for sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement, based on the guidance from ASC 350-20-40-3. Assets and liabilities held for sale at December 31, 2016 are as follows (in thousands): Assets Held for Sale Accounts Receivable $ 98 Inventory 2 Intangible assets 810 Allocated Goodwill 394 Total 1,304 Liabilities Held for Sale Deferred Revenue $ 832 Total $ 832 The Company expects to record an approximate gain of $2.5 million as of the closing date.

Financing Arrangements

Financing Arrangements	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Financing Arrangements	(4) Financing Arrangements In December, 2011, the Company entered into several agreements with entities affiliated with Deerfield Management, a healthcare investment fund (“Deerfield”), pursuant to which Deerfield agreed to provide $15 million in funding to the Company. The agreements consisted of a Facility Agreement (the “Facility Agreement”), a Revenue Purchase Agreement (the “Revenue Purchase Agreement”) and the issuance of warrants to purchase up to 550,000 shares of the Company’s common stock at an exercise price of $3.50 (the “Warrants”). On April 30, 2014, the Company agreed to pay Deerfield $4.1 million to terminate the Revenue Purchase Agreement, which eliminated the ability to extend the last debt payment for an additional year and eliminated the payment obligation for 2017 under the Revenue Purchase Agreement. The Company recorded a loss of $0.9 million in connection with termination of the Revenue Purchase Agreement. In addition, Deerfield exercised their Warrants, for an aggregate purchase price of $1,575,000, and the Company issued 450,000 shares of common stock to Deerfield, pursuant to the terms of the Warrants. The Warrants to purchase an additional 100,000 shares of common stock were cancelled, since these Warrants were exercisable only in the event the Company extended the last debt payment for an additional year. On March 31, 2015, the Company repaid in full the aggregate amount outstanding under the Deerfield Facility Agreement. The Facility Agreement was to mature on December 29, 2016 and was able to be repaid prior to the maturity date at the Company’s option without penalty or premium. The Company used cash on hand to pay the $11.25 million outstanding principal amount due under the Facility Agreement and approximately $162,000 in accrued and unpaid interest on such principal amount. The Company recorded a loss on the extinguishment of debt of approximately $1.7 million at the termination date in the quarter ended March 31, 2015. The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2016 and 2015 (in thousands): December 31, 2016 December 31, 2015 Cash interest expense $ — $ 163 Non-cash — 254 Amortization of debt costs — 13 Amortization of settlement obligations 82 146 Interest expense capital lease 70 220 Capital lease - fair value amortization (89 ) (146 ) Total interest expense $ 63 $ 650 Cash interest expense represents the amount of interest paid in cash under the agreements, which represents the interest of 5.75% on the Facility Agreement that was terminated in March 2015. Non-cash

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consist of the following at December 31 (in thousands): 2016 2015 Accrued salary and related expenses $ 1,878 $ 1,765 Accrued accounts payable 2,269 1,518 Accrued professional fees 316 425 Accrued short term settlement costs 474 418 Other accrued expenses 48 52 Deferred rent 3 42 $ 4,988 $ 4,220

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	(6) Stockholders’ Equity (a) Stock Options The Company has five stock option or stock incentive plans, which are described as follows: The 2002 Stock Option Plan (the “2002 Plan”). The 2002 Plan was adopted by the Company’s stockholders in June 2002. The 2002 Plan provides for the granting of non-qualifying Non-qualifying The 2004 Stock Incentive Plan (the “2004 Plan”). The 2004 Plan was adopted by the Company’s stockholders in June 2004. The 2004 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2004 Plan provides for the granting of non-qualifying Non-qualifying The 2005 Stock Incentive Plan (the “2005 Plan”). The 2005 Plan was adopted by the Company’s stockholders in June 2005. The 2005 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. The 2005 Plan provides for the granting of non-qualifying Non-qualifying The 2007 Stock Incentive Plan (the “2007 Plan”). The 2007 Plan was adopted by the Company’s stockholders in July 2007 and amended in June 2009. The 2007 Plan provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the 2007 Plan, (i) the 2007 Plan provides for a total of 1,050,000 shares of the Company’s common stock to be available for distribution pursuant to the 2007 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the 2007 Plan during any calendar year or part of a year may not exceed 160,000 shares. The 2007 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2007 Plan, determine participants who will be granted awards under the 2007 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2007 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options. With respect to options granted under the 2007 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2016, there were 57,260 shares available for issuance under the 2007 Plan. The 2012 Stock Incentive Plan (the “2012 Plan”). The 2012 Plan was adopted by the Company’s stockholders in May 2012 and amended in May 2014. The 2012 Plan, as amended, provides for the grant of any or all of the following types of awards: (a) stock options, (b) restricted stock, (c) deferred stock and (d) other stock-based awards. Awards may be granted singly, in combination, or in tandem. Subject to anti-dilution adjustments as provided in the amended 2012 Plan, (i) the amended 2012 Plan provides for a total of 1,600,000 shares of the Company’s common stock to be available for distribution pursuant to the amended 2012 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options, restricted stock, deferred stock, or other stock-based awards may be granted to any participant under the amended 2012 Plan during any calendar year or part of a year may not exceed 250,000 shares. The 2012 Plan provides that it will be administered by the Company’s Board of Directors (“Board”) or a committee of two or more members of the Board appointed by the Board. The administrator will generally have the authority to administer the 2012 Plan, determine participants who will be granted awards under the 2012 Plan, the size and types of awards, the terms and conditions of awards and the form and content of the award agreements representing awards. Awards under the 2012 Plan may be granted to employees, directors, consultants and advisors of the Company and its subsidiaries. However, only employees of the Company and its subsidiaries will be eligible to receive options that are designated as incentive stock options. With respect to options granted under the 2012 Plan, the exercise price must be at least 100% (110% in the case of an incentive stock option granted to a 10% stockholder) of the fair market value of the common stock subject to the award, determined as of the date of grant. Restricted stock awards are shares of common stock that are awarded subject to the satisfaction of the terms and conditions established by the administrator. In general, awards that do not require exercise may be made in exchange for such lawful consideration, including services, as determined by the administrator. At December 31, 2016, there were 155,964 shares available for issuance under the 2012 Plan. The 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan was adopted by the Company’s stockholders in May 2016. The 2016 Plan provides for the grant of any or all of the following types of awards: (a) non-qualified Subject to anti-dilution adjustments as provided in the 2016 Plan, (i) the 2016 Plan provides for a total of 1,700,000 shares of the Company’s common stock to be available for distribution pursuant to the 2016 Plan, and (ii) the maximum number of shares of the Company’s common stock with respect to which stock options or stock appreciation rights may be granted to any one individual under the 2016 Plan during any one calendar year period may not exceed 1,000,000 shares. No more than 1,000,000 shares of common stock may be issued in the form of incentive stock options and no more than 50,000 shares of stock may be issued pursuant to awards to non-employee The 2016 Plan provides that it will be administered by the Company’s Compensation Committee. The Compensation Committee has the authority to administer the 2016 Plan, determine participants, from among the individuals eligible for awards, who will be granted awards under the 2016 Plan, make any combination of awards to participants and determine the specific terms and conditions of awards subject to the 2016 Plan. Awards under the 2016 Plan may be granted to full or part-time officers, employees, non-employee With respect to stock options granted under the 2016 Plan, the exercise price will be determined by the Compensation Committee but may not be less than 100% of the fair market value of the common stock subject to the award, determined as of the date of grant. Regarding incentive stock options, including that the aggregate grant date fair market value of the shares of stock with respect to which incentive stock options granted under the 2016 Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any incentive stock option exceeds this limit, it shall constitute a non-qualified A summary of stock option activity for all stock option plans is as follows: Number of Weighted Average Weighted Average Outstanding, January 1, 2014 1,334,955 $ 4.75 Granted 281,043 $ 8.08 Exercised (162,528 ) $ 4.36 Forfeited (35,583 ) $ 13.62 Outstanding, December 31, 2014 1,417,887 $ 4.34 Granted 363,239 $ 6.58 Exercised (79,472 ) $ 4.60 Forfeited (129,656 ) $ 7.38 Outstanding, December 31, 2015 1,571,998 $ 5.05 Granted 127,500 $ 5.46 Exercised (75,583 ) $ 2.62 Forfeited (198,567 ) $ 6.19 Outstanding, December 31, 2016 1,425,348 $ 5.05 6.1 years Exercisable at December 31, 2014 955,210 $ 4.43 Exercisable at December 31, 2015 1,087,725 $ 4.33 Exercisable at December 31, 2016 1,054,211 $ 4.71 5.2 years Available for future grants at December 31, 2016 from all plans: 1,482,947 The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Years Ended December 31, 2016 2015 2014 Cost of revenue $ 6 $ 14 $ 13 Engineering and product development 329 223 165 Marketing and sales 677 659 353 General and administrative expense 1,295 1,239 787 $ 2,307 $ 2,135 $ 1,318 As of December 31, 2016, there was $3.8 million of total unrecognized compensation costs related to unvested options and restricted stock. That cost is expected to be recognized over a weighted average period of 1.1 years. Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Years Ended December 31, 2016 2015 2014 Average risk-free interest rate 0.98% 0.97% 0.85% Expected dividend yield None None None Expected life 3.5 years 3.5 years 3.5 years Expected volatility 68.5% to 75.3% 60.5% to 75.2% 64.2% to 69.4% Weighted average exercise price $5.46 $6.58 $8.09 Weighted average fair value $2.66 $3.17 $3.84 The Company’s 2016, 2015 and 2014, average expected volatility and average expected life is based on the average of the Company’s historical information. The risk-free rate is based on the rate of U.S. Treasury zero-coupon Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2016 2015 2014 Outstanding $ 409 $ 1,910 $ 6,343 Exercisable 409 1,610 4,624 Exercised 201 317 1,081 stock price at 12/31 $ 3.24 $ 5.17 $ 9.17 (b) Restricted Stock The Company’s restricted stock awards typically vest in either one year or three equal annual installments with the first installment vesting one year from grant date. The Company granted a total of 162,500 shares of performance based restricted stock during 2016 with performance measured on meeting a revenue target based on growth for fiscal year 2017 and vesting in three equal installments with the first installment vesting upon measurement of the goal. In addition, a maximum of 108,333 additional shares are available to be earned based on exceeding the revenue goal. Assumptions used to determine the value of performance based grants of restricted stock include the probability of achievement of the specified revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of achieving the performance objectives and compensation cost is re-measured A summary of restricted stock activity for all equity incentive plans is as follows: Years Ended December 31, 2016 2015 2014 Beginning outstanding balance 516,396 309,317 216,250 Granted 345,778 352,666 180,500 Vested (289,030 ) (124,758 ) (85,434 ) Forfeited (61,746 ) (20,829 ) (1,999 ) Ending outstanding balance 511,398 516,396 309,317 Intrinsic values of restricted stock (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2016 2015 2014 Outstanding $ 1,657 $ 2,670 $ 2,836 Vested 936 645 783 stock price at 12/31 $ 3.24 $ 5.17 $ 9.17

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	(7) Income Taxes The components of income tax expense for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands): 2016 2015 2014 Current provision (benefit): Federal $ — $ — $ (44 ) State 69 95 118 $ 69 $ 95 $ 74 Deferred provision: Federal $ 6 $ (65 ) $ 65 State 1 (14 ) 14 $ 7 $ (79 ) $ 79 Total $ 76 $ 16 $ 153 A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2016, 2015 and 2014 is as follows: 2016 2015 2014 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit 2.8 % 2.5 % 5.5 % Net state impact of deferred rate change 0.2 % (0.1 %) 13.0 % Stock compensation expense (3.2 %) (10.7 %) (9.6 %) Tax amortization on goodwill (0.1 %) 0.2 % (9.0 %) Loss on warrant 0.0 % 0.0 % 71.6 % Other permanent differences (0.4 %) (0.1 %) (1.1 %) Change in valuation allowance (37.3 %) (26.6 %) (222.6 %) Tax credits 3.2 % 0.9 % 100.8 % Effective income tax (0.8 %) 0.1 % (17.4 %) Deferred tax assets and liabilities are recognized for the expected future tax consequences of net operating loss carryforwards, tax credit carryforwards and temporary differences between the financial statement carrying amounts and the income tax basis of assets and liabilities. A valuation allowance is applied against any net deferred tax asset if, based on the available evidence, it is more likely than not that the deferred tax assets will not be realized. Deferred income taxes reflect the impact of “temporary differences” between the amount of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. The Company has fully reserved the net deferred tax assets, as it is more likely than not that the deferred tax assets will not be utilized. Deferred tax assets (liabilities) are composed of the following at December 31 (in thousands): 2016 2015 Inventory (Section 263A) $ 418 $ 588 Inventory reserves 105 106 Receivable reserves 65 159 Other accruals 434 591 Deferred revenue 215 367 Accumulated depreciation/amortization 477 417 Stock options 2,558 2,529 Developed technology 3,594 3,554 Tax credits 3,090 2,765 NOL carryforward 40,865 36,706 Net deferred tax assets 51,821 47,782 Valuation allowance (51,821 ) (47,782 ) Goodwill tax amortization (7 ) Deferred tax liability $ (7 ) $ — The increase in net deferred tax assets and corresponding valuation allowance is primarily attributable to additional net operating losses, additional research and development credits, and differences in amortization periods on the Company’s intangible assets. The Company completed an asset acquisition in January 2016 which resulted in $293,307 of goodwill. For book purposes, the goodwill was classified as an indefinite lived asset and tested for impairment each year. For tax, the Company is allowed amortization expense over a 15 year life. Due to the indefinite life of the asset for book purposes, the Company could not assume there would be a deferred tax asset available to offset the liability in future years. This created a tax expense in 2016 equal to the tax effected amount of tax amortization, or $6,844 in 2016. As of December 31, 2016, the Company has net operating loss carryforwards totaling approximately $111.7 million expiring between 2019 and 2036. A portion of the total net operating loss carryforwards amounting to approximately $35.3 million relate to the acquisition of Xoft, Inc. As of December 31, 2016, the Company has provided a valuation allowance for its net operating loss carryforwards due to the uncertainty of the Company’s ability to generate sufficient taxable income in future years to obtain the benefit from the utilization of the net operating loss carryforwards. In the event of a deemed change in control, an annual limitation imposed on the utilization of the net operating losses may result in the expiration of all or a portion of the net operating loss carryforwards. There were no net operating losses utilized for the years ended December 31, 2016 or 2015. The Company currently has approximately $13.8 million (including approximately $9.5 million that relate to Xoft, Inc.) in net operating losses that are subject to limitations, of which approximately $2.0 million (including approximately $473,000 that relates to Xoft, Inc.) can be used annually through 2035. The Company has available tax credit carryforwards (adjusted to reflect provisions of the Tax Reform Act of 1986) to offset future income tax liabilities totaling approximately $3.1 million. The tax credits related to Xoft have been fully reserved for and as a result no deferred tax asset has been recorded. The credits expire in various years through 2036. ASC 740-10 de-recognition, As of December 31, 2016 and 2015, the Company had no unrecognized tax benefits and no adjustments to liabilities or operations were required under ASC 740-10. The Company does not anticipate that it is reasonably possible that unrecognized tax benefits as of December 31, 2016 will significantly change within the next 12 months.

Segment Reporting, Geographical

Segment Reporting, Geographical Information and Major Customers	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment Reporting, Geographical Information and Major Customers	(8) Segment Reporting, Geographical Information and Major Customers (a) Segment Reporting In accordance with FASB Topic ASC 280, “ Segments The Company’s CODM is the Chief Executive Officer (“CEO”). Each reportable segment generates revenue from the sale of medical equipment and related services and/or sale of supplies. The Company has determined there are two segments: Cancer Detection and Cancer Therapy. The Detection segment consists of our advanced image analysis and workflow products, and the Therapy segment consists of our radiation therapy (“Axxent”) products, and related services. The primary factors used by our CODM to allocate resources are based on revenues, gross profit, operating income or loss, and earnings or loss before interest, taxes, depreciation, amortization, and other specific and non-recurring We do not track our assets by operating segment and our CODM does not use asset information by segment to allocate resources or make operating decisions. Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency): Year Ended December 31, 2016 2015 2014 Segment revenues: Detection $ 17,133 $ 19,243 $ 18,604 Therapy 9,205 22,311 25,320 Total Revenue $ 26,338 $ 41,554 $ 43,924 Segment gross profit: Detection $ 15,113 $ 16,019 $ 15,276 Therapy 3,405 13,331 15,951 Segment gross profit $ 18,518 $ 29,350 $ 31,227 Segment operating income (loss): Detection $ 5,694 $ 7,233 $ 7,231 Therapy (7,752 ) (28,405 ) 1,868 Segment operating income (loss) $ (2,058 ) $ (21,172 ) $ 9,099 General, administrative, depreciation and amortization expense $ (7,912 ) $ (8,907 ) $ (8,284 ) Interest expense (63 ) (650 ) (2,640 ) Gain (loss) on fair value of warrant — — 1,835 Other income 10 21 37 Loss on debt extinguishment — (1,723 ) (903 ) Loss before income tax $ (10,023 ) $ (32,431 ) $ (856 ) Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Detection depreciation and amortization Depreciation $ 223 $ 220 $ 188 Amortization 696 532 515 Therapy depreciation and amortization Depreciation $ 970 $ 1,142 $ 844 Amortization 252 1,213 1,739 (b) Geographic Information The Company’s sales are made to customers, distributors and dealers of mammography, electronic brachytherapy equipment and other medical equipment, and to foreign distributors of mammography and electronic brachytherapy equipment. Export sales to a single country did not exceed 10% of total revenue in any year. Total export sales were approximately $2.3 million or 9% of total revenue in 2016, $2.3 million or 6% of total revenue in 2015 and $1.8 million or 4% of total revenue in 2014. As of December 31, 2016 and 2015, the Company had outstanding receivables of $0.3 million and $0.5 million, respectively, from distributors and customers of its products who are located outside of the U.S. (c) Major Customers The Company had one major customer, GE Healthcare, with revenues of approximately $3.9 million in 2016, $4.1 million in 2015, and $4.1 million in 2014 or 15%, 10%, and 9% of total revenue, respectively. Cancer detection products are also sold through OEM partners, including GE Healthcare, Fuji Medical Systems, Siemens Medical, Vital Images and Invivo. For the year ended December 31, 2016, these five OEM partners composed approximately 47% of Detection revenues and 30% of revenue overall. OEM partners composed 53% of Detection revenues and 25% of revenue overall for the year ended December 31, 2015 and 53% of Detection revenues and 22% of revenue overall for the year ended December 31, 2014. OEM partners represented $1.5 million or 28% of outstanding receivables as of December 31, 2016, with GE Healthcare accounting for $1.3 million or 23% of this amount. The two largest Cancer Therapy customers composed $0.6 million or 12% of outstanding receivables as of December 31, 2016. These six customers in total represented $2.1 million or 40% of outstanding receivables as of December 31, 2016.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	(9) Commitments and Contingencies (a) Lease Obligations As of December 31, 2016, the Company had three lease obligations related to its facilities. The Company’s executive offices are leased pursuant to a five-year lease (the “Lease”) that commenced on December 15, 2006, with renewals in January, 2012 and August 2016 consisting of approximately 11,000 square feet of office space located at 98 Spit Brook Road, Suite 100 in Nashua, New Hampshire (the “Premises”). The August 2016 Lease renewal provides for an annual base rent of $184,518 for the period from March 2017 to February 2020. Additionally, the Company is required to pay its proportionate share of the building and real estate tax expenses and obtain insurance for the Premises. The Company leases a facility in San Jose California under a non-cancelable In addition to the foregoing leases relating to its principal properties, the Company also has a lease for an additional facility in Nashua, New Hampshire used for product repairs, manufacturing and warehousing. Rent expense for all leases for the years ended December 31, 2016, 2015 and 2014 was $745,000, $663,000 and $643,000, respectively. Future minimum rental payments due under these agreements as of December 31, 2016 are as follows (in thousands): Fiscal Year Operating 2017 $ 579 2018 738 2019 746 2020 174 Total $ 2,237 (b) Capital lease obligations In connection with the acquisition of the assets of DermEbx and Radion in 2014, the Company assumed two separate equipment lease obligations with payments totaling approximately $2.6 million through May, 2017. The leases were determined to be capital leases and accordingly the equipment was capitalized and a liability of $2.5 million was recorded. As of December 31, 2016, the outstanding liability for the acquired equipment leases was approximately $0.1 million. Future minimum lease payments under all outstanding capital leases are as follows (in thousands): Fiscal Year Capital Leases 2017 $ 89 subtotal minimum lease obligation 89 less interest (3 ) Total, net 86 less current portion (86 ) Long term portion $ — Related Party Lease: Kamal Gogineni is an employee of one of the Company’s subsidiaries and a shareholder of the Company’s common stock. Additionally, Mr. Gogineni is a shareholder of Radion Capital Partners (“RCP”). RCP was the lessor under a lease between RCP and DermEbx (the “Lease”). In connection with the Company’s acquisition of assets of Radion and DermEbx that closed in July 2014, one of the assets and obligations that the Company acquired was the Lease. Pursuant to the Lease, the Company is obligated to pay a total of $0.1 million and the liability is included in the minimum lease payments above, with remaining annual payments of $76,000 in 2017. (c) Other Commitments The Company has non-cancelable (d) Employment Agreements The Company has entered into employment agreements with certain key executives. The employment agreements provide for minimum annual salaries and performance-based annual bonus compensation as defined in their respective agreements. In addition, the employment agreements provide that if employment is terminated without cause, the executive will receive an amount equal to their respective base salary then in effect for the greater of the remainder of the original term of employment or, for Mr. Ferry, a period of two years from the date of termination, for Mr. Christopher and Ms. Stevens, a period of eighteen months from the date of termination, in each case, plus the pro rata portion of any annual bonus earned in any employment year through the date of termination. (e) Foreign Tax Claim In July 2007, a dissolved former Canadian subsidiary of the Company, CADx Medical Systems Inc. (“CADx Medical”), received a tax re-assessment re-assessment re-assessment (f) Royalty Obligations In connection with prior litigation, the Company received a nonexclusive, irrevocable, perpetual, worldwide license, including the right to sublicense certain Hologic patents, and a non-compete non-compete During December, 2011, the Company settled litigation with Zeiss and as of December 31, 2016, has a remaining obligation to pay $0.5 million in June 2017. The present value of the liability is estimated at approximately $0.4 million as of December 31, 2016. (g) Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	(10) Quarterly Financial Data Net sales Gross Net loss Income (loss) Weighted average number of 2016 First quarter $ 6,038 $ 4,186 $ (2,533 ) ($ 0.16 ) 15,826 Second quarter 7,369 5,702 $ (1,575 ) ($ 0.10 ) 15,904 Third quarter 6,003 4,101 $ (2,675 ) ($ 0.17 ) 15,957 Fourth quarter 6,928 4,529 $ (3,316 ) ($ 0.20 ) 16,214 2015 First quarter $ 13,220 $ 9,362 $ (1,857 ) ($ 0.12 ) 15,605 Second quarter 11,143 7,878 $ (27,786 )* ($ 1.77 ) 15,679 Third quarter 9,582 6,821 $ (402 ) ($ 0.03 ) 15,725 Fourth quarter 7,609 5,289 $ (2,402 ) ($ 0.15 ) 15,733 (*) - includes goodwill and long-lived asset impairment of $27.4 million

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Nature of Operations and Use of Estimates	(a) Nature of Operations and Use of Estimates iCAD, Inc. and subsidiaries (the “Company” or “iCAD”) is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company has grown primarily through acquisitions to become a broad player in the oncology market. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, MRI and CT, and the Xoft System which is an isotope-free cancer treatment platform technology. CAD is reimbursable in the U.S. under federal and most third-party insurance programs. The Company intends to continue the extension of its image analysis and clinical decision support solutions for mammography, MRI and CT imaging. iCAD believes that advances in digital imaging techniques should bolster its efforts to develop additional commercially viable CAD/advanced image analysis and workflow products. The Company’s management believes that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes resulting in a market demand that will drive top line growth. The Company’s headquarters are located in Nashua, New Hampshire, with manufacturing and contract manufacturing facilities in New Hampshire and Massachusetts, and an operations, research, development, manufacturing and warehousing facility in San Jose, California. The Company operates in two segments: Cancer Detection (“Detection”) and Cancer Therapy (“Therapy”). The Detection segment consists of advanced image analysis and workflow products, and the Therapy segment consists of radiation therapy products. The Company sells its products throughout the world through its direct sales organization as well as through various OEM partners, distributors and resellers. See Note 8 for segment, major customer and geographical information. The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. It is reasonably possible that changes may occur in the near term that would affect management’s estimates with respect to assets and liabilities.
Principles of Consolidation	(b) Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: Xoft, Inc. and Xoft Solutions, LLC. All material inter-company transactions and balances have been eliminated in consolidation.
Cash and cash equivalents	(c) Cash and cash equivalents The Company defines cash and cash equivalents as all bank accounts, money market funds, deposits and other money market instruments with original maturities of 90 days or less, which are unrestricted as to withdrawal. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances. Insurance coverage is $250,000 per depositor at each financial institution, and the Company’s non-interest
Financial instruments	(d) Financial instruments Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and notes payable. Due to their short term nature and market rates of interest, the carrying amounts of the financial instruments approximated fair value as of December 31, 2016 and 2015.
Accounts Receivable and Allowance for Doubtful Accounts	(e) Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are customer obligations due under normal trade terms. Credit limits are established through a process of reviewing the financial history and stability of each customer. The Company performs continuing credit evaluations of its customers’ financial condition and generally does not require collateral. The Company’s policy is to maintain allowances for estimated losses from the inability of its customers to make required payments. The Company’s senior management reviews accounts receivable on a periodic basis to determine if any receivables may potentially be uncollectible. The Company includes any accounts receivable balances that it determines may likely be uncollectible, along with a general reserve for estimated probable losses based on historical experience, in its overall allowance for doubtful accounts. An amount would be written off against the allowance after all attempts to collect the receivable had failed. Based on the information available, the Company believes the allowance for doubtful accounts as of December 31, 2016 and 2015 is adequate. The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2016 (in thousands): 2016 2015 2014 Balance at beginning of period $ 236 $ 203 $ 73 Additions charged to costs and expenses 177 383 167 Reductions (241 ) (350 ) (37 ) Balance at end of period $ 172 $ 236 $ 203
Inventory	(f) Inventory Inventory is valued at the lower of cost or market value, with cost determined by the first-in, first-out As of December 31, 2016 2015 Raw materials $ 2,503 $ 2,900 Work in process 75 154 Finished Goods 1,149 1,261 Inventory $ 3,727 $ 4,315
Property and Equipment	(g) Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 years Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5
Long Lived Assets	(h) Long Lived Assets In accordance with FASB ASC Topic 360, “Property, Plant and Equipment”, (“ASC 360”), the Company assesses long-lived assets for impairment if events and circumstances indicate it is more likely than not that the fair value of the asset group is less than the carrying value of the asset group. ASC 360-10-35 360-10-35-21, • A significant decrease in the market price of a long-lived asset (asset group); • A significant adverse change in the extent or manner in which a long-lived asset (asset group) is being used or in its physical condition; • A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset (asset group), including an adverse action or assessment by a regulator; • An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset (asset group); • A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset (asset group). As a result of external factors and general uncertainty related to reimbursement for the treatment of non-melanoma In accordance with ASC 360-10-35-17, In connection with the preparation of the financial statements for the second quarter ended June 30, 2015, the Company completed its analysis pursuant to ASC 360-10-35-17 A considerable amount of judgment and assumptions are required in performing the impairment tests, principally in determining the fair value of the Asset Group. While the Company believes the judgments and assumptions are reasonable, different assumptions could change the estimated fair values, and, therefore additional impairment charges could be required. Significant negative industry or economic trends, disruptions to the Company’s business, loss of significant customers, inability to effectively integrate acquired businesses, unexpected significant changes or planned changes in use of the assets may adversely impact the assumptions used in the fair value estimates and ultimately result in future impairment charges. Intangible assets subject to amortization consist primarily of patents, technology, customer relationships and trade names purchased in the Company’s previous acquisitions. These assets, which include assets from the acquisition of the assets of VuComp, DermEbx and Radion and the acquisition of Xoft, Inc., are amortized on a straight-line basis consistent with the pattern of economic benefit over their estimated useful lives of 5 to 15 years. A summary of intangible assets for 2016 and 2015 are as follows (in thousands): 2016 2015 Weighted Gross Carrying Amount Patents and licenses $ 583 $ 579 5 years Technology 9,567 14,075 10 years Customer relationships 292 268 7 years Tradename 259 248 10 years Total amortizable intangible assets 10,701 15,170 Accumulated Amortization Patents and licenses $ 477 $ 451 Technology 6,754 9,996 Customer relationships 28 201 Tradename 259 248 Total accumulated amortization 7,518 10,896 Total amortizable intangible assets, net $ 3,183 $ 4,274 Amortization expense related to intangible assets was approximately $983,000, $1,768,000 and $2,270,000 for the years ended December 31, 2016, 2015, and 2014, respectively. Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2017 $ 574 2018 511 2019 499 2020 370 2021 311 Thereafter 918 $ 3,183
Goodwill	(i) Goodwill In accordance with FASB Accounting Standards Codification (“ASC”) Topic 350-20, “Intangibles - Goodwill and Other” 350-20”), Factors the Company considers important, which could trigger an impairment of such asset, include the following: • significant underperformance relative to historical or projected future operating results; • significant changes in the manner or use of the assets or the strategy for the Company’s overall business; • significant negative industry or economic trends; • significant decline in the Company’s stock price for a sustained period; and • a decline in the Company’s market capitalization below net book value. The Company would record an impairment charge if such an assessment were to indicate that the fair value of a reporting unit was less than the carrying value. In evaluating potential impairments outside of the annual measurement date, judgment is required in determining whether an event has occurred that may impair the value of goodwill or intangible assets. The Company utilizes either discounted cash flow models or other valuation models, such as comparative transactions and market multiples, to determine the fair value of reporting units. The Company makes assumptions about future cash flows, future operating plans, discount rates, comparable companies, market multiples, purchase price premiums and other factors in those models. Different assumptions and judgment determinations could yield different conclusions that would result in an impairment charge to income in the period that such change or determination was made. As a result of external factors and general uncertainty related to reimbursement for non-melanoma The implied fair value of the Therapy reporting unit was determined in the same manner as the manner in which the amount of goodwill recognized in a business combination is determined. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of goodwill. The Company identified the intangible assets that were valued during this process, including technology, customer relationships and trade-names. The allocation process was performed only for purposes of testing goodwill for impairment. The Company determined the fair value of the Therapy reporting unit based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. This approach was selected as it measures the income producing assets, primarily technology and customer relationships. This method estimates the fair value based upon the ability to generate future cash flows, which is particularly applicable when future profit margins and growth are expected to vary significantly from historical operating results. The Company uses internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for the reporting unit. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 17% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting unit to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. Other significant assumptions include terminal value margin rates, future capital expenditures, and changes in future working capital requirements. While there are inherent uncertainties related to the assumptions used and to the application of these assumptions to this analysis, the income approach provides a reasonable estimate of the fair value of the Therapy reporting unit. The Step 2 test resulted in an approximate fair value of goodwill of $5.7 million which resulted in a goodwill impairment loss of $14.0 million for the quarter ended June 30, 2015. The Company performed an annual impairment assessment at October 1, 2016 and compared the fair value of each reporting unit to its carrying value as of this date. Fair value was approximately 816% of carrying value for the Detection reporting unit and 126% of carrying value for the Therapy reporting unit. The carrying values of the reporting units were determined based on an allocation of our assets and liabilities through specific allocation of certain assets and liabilities to the reporting units and an apportionment of the remaining net assets based on the relative size of the reporting units’ revenues and operating expenses compared to the Company as a whole. The determination of reporting units also requires management judgment. The Company determined the fair values for each reporting unit using a weighting of the income approach and the market approach. For purposes of the income approach, fair value is determined based on the present value of estimated future cash flows, discounted at an appropriate risk adjusted rate. The Company used internal forecasts to estimate future cash flows and includes an estimate of long-term future growth rates based on the most recent views of the long-term forecast for each segment. Accordingly, actual results can differ from those assumed in the forecasts. The discount rate of approximately 15% is derived from a capital asset pricing model and analyzing published rates for industries relevant to the reporting units to estimate the cost of equity financing. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective businesses and in the internally developed forecasts. In the market approach, the Company uses a valuation technique in which values are derived based on market prices of publicly traded companies with similar operating characteristics and industries. A market approach allows for comparison to actual market transactions and multiples. It can be somewhat limited in its application because the population of potential comparable publicly-traded companies can be limited due to differing characteristics of the comparative business and ours, as well as market data may not be available for divisions within larger conglomerates or non-public The Company corroborated the total fair values of the reporting units using a market capitalization approach; however, this approach cannot be used to determine the fair value of each reporting unit value. The blend of the income approach and market approach is more closely aligned to the business profile of the Company, including markets served and products available. In addition, required rates of return, along with uncertainties inherent in the forecast of future cash flows, are reflected in the selection of the discount rate. In addition, under the blended approach, reasonably likely scenarios and associated sensitivities can be developed for alternative future states that may not be reflected in an observable market price. The Company will assess each valuation methodology based upon the relevance and availability of the data at the time the valuation is performed and weight the methodologies appropriately. In April 2015, the Company acquired VuComp’s M-Vu ® In January 2016, the Company completed the acquisition of VuComp’s M-Vu In December, 2016, the Company entered into an Asset Purchase Agreement with Invivo Corporation. The Company will sell and convey to Buyer all right, title and interest to certain intellectual property relating to the VersaVue Software and the DynaCAD product and related assets. As a result of the agreement, the Company determined that it had assets held for sale as of December 31, 2016 and the sale constituted the sale of a business. As of December 31, 2016, the Company allocated $394,000 of goodwill to assets held for sale. The allocation was based on the fair value of the assets sold relative to the fair value of the Detection reporting unit as of the date of the agreement. A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Balance at December 31, 2014 7,663 19,600 27,263 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (13,981 ) (40,809 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097
Revenue Recognition	(j) Revenue Recognition The Company recognizes revenue primarily from the sale of products, services and supplies. Revenue is recognized when delivery has occurred, persuasive evidence of an arrangement exists, fees are fixed or determinable and collectability of the related receivable is probable. For product revenue, delivery has occurred upon shipment provided title and risk of loss have passed to the customer. Services and supplies revenue are considered to be delivered as the services are performed or over the estimated life of the supply agreement. The Company recognizes revenue from the sale of its digital, film-based CAD and cancer therapy products and services in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Update No. 2009-13, Multiple-Deliverable Revenue Arrangement 2009-13”) No. 2009-14, Certain Arrangements That Contain Software Elements 2009-14”) 985-605, “Software” 985-605”). Leases” The Company uses customer purchase orders that are subject to the Company’s terms and conditions or, in the case of an Original Equipment Manufacturer (“OEM”) are governed by distribution agreements. In accordance with the Company’s distribution agreements, the OEM does not have a right of return, and title and risk of loss passes to the OEM upon shipment. The Company generally ships Free On Board shipping point and uses shipping documents and third-party proof of delivery to verify delivery and transfer of title. In addition, the Company assesses whether collection is probable by considering a number of factors, including past transaction history with the customer and the creditworthiness of the customer, as obtained from third party credit references. If the terms of the sale include customer acceptance provisions and compliance with those provisions cannot be demonstrated, all revenue is deferred and not recognized until such acceptance occurs. The Company considers all relevant facts and circumstances in determining when to recognize revenue, including contractual obligations to the customer, the customer’s post-delivery acceptance provisions, if any, and the installation process. The Company has determined that iCAD’s digital and film based sales generally follow the guidance of FASB ASC Topic 605 “ Revenue Recognition 2009-14. 2009-13. Revenue from certain CAD products is recognized in accordance with ASC 985-605. The Company recognizes post contract customer support revenue together with the initial licensing fee for certain MRI products in accordance with 985-605-25-71. Sales of the Company’s Therapy segment products typically include a controller, accessories, source agreements and services. The Company allocates revenue to the deliverables in the arrangement based on the BESP in accordance with ASU 2009-13. The Company defers revenue from the sale of certain service contracts and recognizes the related revenue on a straight-line basis in accordance with ASC Topic 605-20, Services
Cost of Revenue	(k) Cost of Revenue Cost of revenue consists of the costs of products purchased for resale, cost relating to service including costs of service contracts to maintain equipment after the warranty period, inbound freight and duty, manufacturing, warehousing, material movement, inspection, scrap, rework, depreciation and in-house
Warranty Costs	(l) Warranty Costs The Company provides for the estimated cost of standard product warranty against defects in material and workmanship based on historical warranty trends, including the cost of product returns during the warranty period. Warranty provisions and claims for the years ended December 31, 2016, 2015 and 2014, were as follows (in thousands): 2016 2015 2014 Beginning accrual balance $ 19 $ 14 $ 25 Warranty provision 47 54 58 Usage (55 ) (49 ) (69 ) Ending accrual balance $ 11 $ 19 $ 14 The warranty accrual above includes long-term warranty obligations of $0, $2,000 and $5,000 for the years ended December 31, 2016, 2015 and 2014 respectively.
Engineering and Product Development Costs	(m) Engineering and Product Development Costs Engineering and product development costs relate to research and development efforts including Company sponsored clinical trials which are expensed as incurred.
Advertising Costs	(n) Advertising Costs The Company expenses advertising costs as incurred. Advertising expense for the years ended December 31, 2016, 2015 and 2014 was approximately $955,000, $950,000 and $882,000 respectively.
Net Loss per Common Share	(o) Net Loss per Common Share The Company follows FASB ASC 260-10, A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss available to common shareholders $ (10,099 ) $ (32,447 ) $ (1,009 ) Basic shares used in the calculation of earnings per share 15,932 15,686 14,096 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 15,932 15,686 14,096 Net loss per share : Basic $ (0.63 ) $ (2.07 ) $ (0.07 ) Diluted $ (0.63 ) $ (2.07 ) $ (0.07 ) The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2016 2015 2014 Common stock options 1,425,348 1,571,998 1,417,887 Restricted Stock 511,398 516,396 309,317 1,936,746 2,088,394 1,727,204 Restricted common stock can be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares were excluded from the computation of basic loss per share as these shares are not considered outstanding until vested.
Income Taxes	(p) Income Taxes The Company follows the liability method under ASC Topic 740, “Income Taxes”, (“ASC 740”). The primary objectives of accounting for taxes under ASC 740 are to (a) recognize the amount of tax payable for the current year and (b) recognize the amount of deferred tax liability or asset for the future tax consequences of events that have been reflected in the Company’s financial statements or tax returns. The Company has provided a full valuation allowance against its deferred tax assets at December 31, 2016 and 2015, as it is more likely than not that the deferred tax asset will not be realized. Any subsequent changes in the valuation allowance will be recorded through operations in the provision (benefit) for income taxes. ASC 740-10 740-10 de-recognition,
Stock-Based Compensation	(q) Stock-Based Compensation The Company maintains stock-based incentive plans, under which it provides stock incentives to employees, directors and contractors. The Company may grant to employees, directors and contractors, options to purchase common stock at an exercise price equal to the market value of the stock at the date of grant. The Company may grant restricted stock to employees and directors. The underlying shares of the restricted stock grant are not issued until the shares vest, and compensation expense is based on the stock price of the shares at the time of grant. The Company follows FASB ASC Topic 718, “Compensation – Stock Compensation” (“ASC 718”), for all stock-based compensation. Under this application, the Company is required to record compensation expense over the vesting period for all awards granted. The Company uses the Black-Scholes option pricing model to value stock options which requires extensive use of accounting judgment and financial estimates, including estimates of the expected term participants will retain their vested stock options before exercising them, the estimated volatility of its common stock price over the expected term, the risk free rate, expected dividend yield, and the number of options that will be forfeited prior to the completion of their vesting requirements. The fair value of restricted stock is determined based on the stock price of the underlying option on the date of the grant. The Company granted performance based restricted stock during 2016 based on achievement of certain revenue targets. Compensation cost for performance based restricted stock requires significant judgment regarding probability of the performance objectives and compensation cost is re-measured Application of alternative assumptions could produce significantly different estimates of the fair value of stock-based compensation and consequently, the related amounts recognized in the Consolidated Statements of Operations.
Fair Value Measurements	(r) Fair Value Measurements The Company follows the provisions of FASB ASC Topic 820, “Fair Value Measurement and Disclosures” (“ASC 820”). This topic defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following: • Level 1 - Quoted prices in active markets for identical assets or liabilities. • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s assets that are measured at fair value on a recurring basis relate to the Company’s money market accounts. The money market funds are included in cash and cash equivalents in the accompanying balance sheet, and are considered a level 1 investment as they are valued at quoted market prices in active markets. The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Fair value measurements using: (000’s) as of December 31, 2015 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 13,577 $ — $ — $ 13,577 Total Assets $ 13,577 $ — $ — $ 13,577 Items Measured at Fair Value on a Nonrecurring Basis Certain assets, including long-lived assets and goodwill, are measured at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be impaired. In 2015 the Company recorded a $27.4 million impairment consisting of $14.0 million related to goodwill and $13.4 million related to long-lived assets as discussed in Note (h) and Note (i) and re-measured
Recently Issued Accounting Standards	(s) Recently Issued Accounting Standards In May 2014, the FASB issued ASU No. 2014-09, 2014-09, 2016-08, 2016-10, No. 2014-09. 2014-09 one-year 2014-09 2014-09, In February 2016, the FASB issued ASU No. 2016-02, right-of-use off-balance In March 2016, the FASB issued ASU 2016-09, 2016-09 In August 2016, the FASB issued ASU 2016-15,
Segment Reporting	In accordance with FASB Topic ASC 280, “ Segments
Litigation	(g) Litigation The Company may be a party to various legal proceedings and claims arising out of the ordinary course of its business. Although the final results of all such matters and claims cannot be predicted with certainty, the Company currently believes that there are no current proceedings or claims pending against it of which the ultimate resolution would have a material adverse effect on its financial condition or results of operations. However, should we fail to prevail in any legal matter or should several legal matters be resolved against us in the same reporting period, such matters could have a material adverse effect on our operating results and cash flows for that particular period. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Allowance for Doubtful Accounts	The following table summarizes the allowance for doubtful accounts for the three years ended December 31, 2016 (in thousands): 2016 2015 2014 Balance at beginning of period $ 236 $ 203 $ 73 Additions charged to costs and expenses 177 383 167 Reductions (241 ) (350 ) (37 ) Balance at end of period $ 172 $ 236 $ 203
Schedule of Current Inventory	At December 31, 2016 and 2015, inventories consisted of the following (in thousands): As of December 31, 2016 2015 Raw materials $ 2,503 $ 2,900 Work in process 75 154 Finished Goods 1,149 1,261 Inventory $ 3,727 $ 4,315
Schedule of Property and Equipment Estimated Useful Lives	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets or the remaining lease term, if shorter, for leasehold improvements (see below). Estimated life Equipment 3-5 years Leasehold improvements 3-5 Furniture and fixtures 3-5 Marketing assets 3-5
Schedule of Intangible Assets	A summary of intangible assets for 2016 and 2015 are as follows (in thousands): 2016 2015 Weighted Gross Carrying Amount Patents and licenses $ 583 $ 579 5 years Technology 9,567 14,075 10 years Customer relationships 292 268 7 years Tradename 259 248 10 years Total amortizable intangible assets 10,701 15,170 Accumulated Amortization Patents and licenses $ 477 $ 451 Technology 6,754 9,996 Customer relationships 28 201 Tradename 259 248 Total accumulated amortization 7,518 10,896 Total amortizable intangible assets, net $ 3,183 $ 4,274
Schedule of Expected Amortization Expense	Estimated remaining amortization of the Company’s intangible assets is as follows (in thousands): For the years ended December 31: Estimated 2017 $ 574 2018 511 2019 499 2020 370 2021 311 Thereafter 918 $ 3,183
Roll Forward of Goodwill Activity by Reportable Segment	A rollforward of goodwill activity by reportable segment is as follows (in thousands): Detection Therapy Total Accumulated Goodwill $ — $ — $ 47,937 Accumulated impairment — — (26,828 ) Fair value allocation 7,663 13,446 — Acquisition of DermEbx and Radion — 6,154 6,154 Balance at December 31, 2014 7,663 19,600 27,263 Acquisition measurement period adjustments — 116 116 Acquisition of VuComp 800 — 800 Impairment — (13,981 ) (13,981 ) Balance at December 31, 2015 8,463 5,735 14,198 Acquisition of VuComp 293 — 293 Sale of MRI assets (394 ) — (394 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097 Accumulated Goodwill 699 6,270 54,906 Fair value allocation 7,663 13,446 — Accumulated impairment — (13,981 ) (40,809 ) Balance at December 31, 2016 $ 8,362 $ 5,735 $ 14,097
Roll forward of Warranty Cost	Warranty provisions and claims for the years ended December 31, 2016, 2015 and 2014, were as follows (in thousands): 2016 2015 2014 Beginning accrual balance $ 19 $ 14 $ 25 Warranty provision 47 54 58 Usage (55 ) (49 ) (69 ) Ending accrual balance $ 11 $ 19 $ 14
Calculation of Net Loss Per Share	A summary of the Company’s calculation of net loss per share is as follows (in thousands, except per share amounts): 2016 2015 2014 Net loss available to common shareholders $ (10,099 ) $ (32,447 ) $ (1,009 ) Basic shares used in the calculation of earnings per share 15,932 15,686 14,096 Effect of dilutive securities: Stock options — — — Restricted stock — — — Diluted shares used in the calculation of earnings per share 15,932 15,686 14,096 Net loss per share : Basic $ (0.63 ) $ (2.07 ) $ (0.07 ) Diluted $ (0.63 ) $ (2.07 ) $ (0.07 )
Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share	The following table summarizes the number of shares of common stock for securities, warrants and restricted stock that were not included in the calculation of diluted net loss per share because such shares are antidilutive: 2016 2015 2014 Common stock options 1,425,348 1,571,998 1,417,887 Restricted Stock 511,398 516,396 309,317 1,936,746 2,088,394 1,727,204
Assets which are Measured at Fair Value on a Recurring Basis	The following table sets forth Company’s assets which are measured at fair value on a recurring basis by level within the fair value hierarchy. Fair value measurements using: (000’s) as of December 31, 2016 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 6,622 $ — $ — $ 6,622 Total Assets $ 6,622 $ — $ — $ 6,622 Fair value measurements using: (000’s) as of December 31, 2015 Level 1 Level 2 Level 3 Total Assets Money market accounts $ 13,577 $ — $ — $ 13,577 Total Assets $ 13,577 $ — $ — $ 13,577

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
VuComp Cancer Detection Portfolio [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life: Amount (000’s) Estimated amortizable life Current assets $ 84 Property and equipment 65 3 Years Identifiable intangible assets 699 1-10 Years Goodwill 293 Current liabilities (280 ) Long-term liabilities (606 ) Purchase price $ 255
VuComp M-Vu Breast Density Product [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following is a summary of the allocation of the total purchase price based on the estimated fair values as of the date of the acquisition and the amortizable life (in thousands): Amount Estimated Amortizable Life Developed Technology $ 900 8 years 9 months Goodwill 800 Purchase price $ 1,700
MVu Breast Density [Member]
Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and Liabilities Assumed	As a result the Company recorded a gain on litigation settlement of $249,000 in the first quarter of 2016, which is a component of the purchase price as noted below: Amount (000’s) Cash $ 6 Acquisition litigation settlement 249 Purchase price $ 255

Assets and Liabilities Held f21

Assets and Liabilities Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Assets and Liabilities Held for Sale	Assets and liabilities held for sale at December 31, 2016 are as follows (in thousands): Assets Held for Sale Accounts Receivable $ 98 Inventory 2 Intangible assets 810 Allocated Goodwill 394 Total 1,304 Liabilities Held for Sale Deferred Revenue $ 832 Total $ 832

Financing Arrangements (Tables)

Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Interest Expense in Consolidated Income Statement	The following amounts are included in interest expense in our consolidated statement of operations for the years ended December 31, 2016 and 2015 (in thousands): December 31, 2016 December 31, 2015 Cash interest expense $ — $ 163 Non-cash — 254 Amortization of debt costs — 13 Amortization of settlement obligations 82 146 Interest expense capital lease 70 220 Capital lease - fair value amortization (89 ) (146 ) Total interest expense $ 63 $ 650

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses consist of the following at December 31 (in thousands): 2016 2015 Accrued salary and related expenses $ 1,878 $ 1,765 Accrued accounts payable 2,269 1,518 Accrued professional fees 316 425 Accrued short term settlement costs 474 418 Other accrued expenses 48 52 Deferred rent 3 42 $ 4,988 $ 4,220

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Stock Option Activity for all Stock Option Plans	A summary of stock option activity for all stock option plans is as follows: Number of Weighted Average Weighted Average Outstanding, January 1, 2014 1,334,955 $ 4.75 Granted 281,043 $ 8.08 Exercised (162,528 ) $ 4.36 Forfeited (35,583 ) $ 13.62 Outstanding, December 31, 2014 1,417,887 $ 4.34 Granted 363,239 $ 6.58 Exercised (79,472 ) $ 4.60 Forfeited (129,656 ) $ 7.38 Outstanding, December 31, 2015 1,571,998 $ 5.05 Granted 127,500 $ 5.46 Exercised (75,583 ) $ 2.62 Forfeited (198,567 ) $ 6.19 Outstanding, December 31, 2016 1,425,348 $ 5.05 6.1 years Exercisable at December 31, 2014 955,210 $ 4.43 Exercisable at December 31, 2015 1,087,725 $ 4.33 Exercisable at December 31, 2016 1,054,211 $ 4.71 5.2 years
Stock-Based Compensation Expense Including Options and Restricted Stock by Category	The Company’s stock-based compensation expense, including options and restricted stock by category is as follows (amounts in thousands): Years Ended December 31, 2016 2015 2014 Cost of revenue $ 6 $ 14 $ 13 Engineering and product development 329 223 165 Marketing and sales 677 659 353 General and administrative expense 1,295 1,239 787 $ 2,307 $ 2,135 $ 1,318
Options Granted under the Company's Stock Incentive Plans, Valuation Assumptions and Fair Values	Options granted under the stock incentive plans were valued utilizing the Black-Scholes model using the following assumptions and had the following fair values: Years Ended December 31, 2016 2015 2014 Average risk-free interest rate 0.98% 0.97% 0.85% Expected dividend yield None None None Expected life 3.5 years 3.5 years 3.5 years Expected volatility 68.5% to 75.3% 60.5% to 75.2% 64.2% to 69.4% Weighted average exercise price $5.46 $6.58 $8.09 Weighted average fair value $2.66 $3.17 $3.84
Summary of Intrinsic Values of Options and Closing Market Price	Intrinsic values of options (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2016 2015 2014 Outstanding $ 409 $ 1,910 $ 6,343 Exercisable 409 1,610 4,624 Exercised 201 317 1,081 stock price at 12/31 $ 3.24 $ 5.17 $ 9.17
Summary of Restricted Stock Activity for All Equity Incentive Plans	A summary of restricted stock activity for all equity incentive plans is as follows: Years Ended December 31, 2016 2015 2014 Beginning outstanding balance 516,396 309,317 216,250 Granted 345,778 352,666 180,500 Vested (289,030 ) (124,758 ) (85,434 ) Forfeited (61,746 ) (20,829 ) (1,999 ) Ending outstanding balance 511,398 516,396 309,317
Summary of Intrinsic Values of Restricted Stock and Closing Market Price	Intrinsic values of restricted stock (in thousands) and the closing market price used to determine the intrinsic values are as follows: Years Ended December 31, 2016 2015 2014 Outstanding $ 1,657 $ 2,670 $ 2,836 Vested 936 645 783 stock price at 12/31 $ 3.24 $ 5.17 $ 9.17

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Components of Income Tax Expense	The components of income tax expense for the years ended December 31, 2016, 2015 and 2014 are as follows (in thousands): 2016 2015 2014 Current provision (benefit): Federal $ — $ — $ (44 ) State 69 95 118 $ 69 $ 95 $ 74 Deferred provision: Federal $ 6 $ (65 ) $ 65 State 1 (14 ) 14 $ 7 $ (79 ) $ 79 Total $ 76 $ 16 $ 153
Summary of Effective and the Federal Statutory Income Tax Rate	A summary of the differences between the Company’s effective income tax rate and the Federal statutory income tax rate for the years ended December 31, 2016, 2015 and 2014 is as follows: 2016 2015 2014 Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of federal benefit 2.8 % 2.5 % 5.5 % Net state impact of deferred rate change 0.2 % (0.1 %) 13.0 % Stock compensation expense (3.2 %) (10.7 %) (9.6 %) Tax amortization on goodwill (0.1 %) 0.2 % (9.0 %) Loss on warrant 0.0 % 0.0 % 71.6 % Other permanent differences (0.4 %) (0.1 %) (1.1 %) Change in valuation allowance (37.3 %) (26.6 %) (222.6 %) Tax credits 3.2 % 0.9 % 100.8 % Effective income tax (0.8 %) 0.1 % (17.4 %)
Deferred Tax Assets (Liabilities)	Deferred tax assets (liabilities) are composed of the following at December 31 (in thousands): 2016 2015 Inventory (Section 263A) $ 418 $ 588 Inventory reserves 105 106 Receivable reserves 65 159 Other accruals 434 591 Deferred revenue 215 367 Accumulated depreciation/amortization 477 417 Stock options 2,558 2,529 Developed technology 3,594 3,554 Tax credits 3,090 2,765 NOL carryforward 40,865 36,706 Net deferred tax assets 51,821 47,782 Valuation allowance (51,821 ) (47,782 ) Goodwill tax amortization (7 ) Deferred tax liability $ (7 ) $ —

Segment Reporting, Geographic26

Segment Reporting, Geographical Information and Major Customers (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss	Segment revenues, gross profit, segment operating income or loss, and a reconciliation of segment operating income or loss to GAAP loss before income tax is as follows (in thousands, including prior periods which have been presented for consistency): Year Ended December 31, 2016 2015 2014 Segment revenues: Detection $ 17,133 $ 19,243 $ 18,604 Therapy 9,205 22,311 25,320 Total Revenue $ 26,338 $ 41,554 $ 43,924 Segment gross profit: Detection $ 15,113 $ 16,019 $ 15,276 Therapy 3,405 13,331 15,951 Segment gross profit $ 18,518 $ 29,350 $ 31,227 Segment operating income (loss): Detection $ 5,694 $ 7,233 $ 7,231 Therapy (7,752 ) (28,405 ) 1,868 Segment operating income (loss) $ (2,058 ) $ (21,172 ) $ 9,099 General, administrative, depreciation and amortization expense $ (7,912 ) $ (8,907 ) $ (8,284 ) Interest expense (63 ) (650 ) (2,640 ) Gain (loss) on fair value of warrant — — 1,835 Other income 10 21 37 Loss on debt extinguishment — (1,723 ) (903 ) Loss before income tax $ (10,023 ) $ (32,431 ) $ (856 )
Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss)	Segment depreciation and amortization included in segment operating income (loss) is as follows (in thousands): Detection depreciation and amortization Depreciation $ 223 $ 220 $ 188 Amortization 696 532 515 Therapy depreciation and amortization Depreciation $ 970 $ 1,142 $ 844 Amortization 252 1,213 1,739

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments	Future minimum rental payments due under these agreements as of December 31, 2016 are as follows (in thousands): Fiscal Year Operating 2017 $ 579 2018 738 2019 746 2020 174 Total $ 2,237
Future Minimum Lease Payments under Non-cancelable Capital Leases	Future minimum lease payments under all outstanding capital leases are as follows (in thousands): Fiscal Year Capital Leases 2017 $ 89 subtotal minimum lease obligation 89 less interest (3 ) Total, net 86 less current portion (86 ) Long term portion $ —

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data	Net sales Gross Net loss Income (loss) Weighted average number of 2016 First quarter $ 6,038 $ 4,186 $ (2,533 ) ($ 0.16 ) 15,826 Second quarter 7,369 5,702 $ (1,575 ) ($ 0.10 ) 15,904 Third quarter 6,003 4,101 $ (2,675 ) ($ 0.17 ) 15,957 Fourth quarter 6,928 4,529 $ (3,316 ) ($ 0.20 ) 16,214 2015 First quarter $ 13,220 $ 9,362 $ (1,857 ) ($ 0.12 ) 15,605 Second quarter 11,143 7,878 $ (27,786 )* ($ 1.77 ) 15,679 Third quarter 9,582 6,821 $ (402 ) ($ 0.03 ) 15,725 Fourth quarter 7,609 5,289 $ (2,402 ) ($ 0.15 ) 15,733 (*) - includes goodwill and long-lived asset impairment of $27.4 million

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Additional Information (Detail)	Apr. 30, 2015USD ($)	Apr. 29, 2015USD ($)	Jan. 31, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2016USD ($)Segment	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business segment | Segment					2
Maturity for cash and cash equivalents					90 days
Insurance coverage					$ 250,000
Interest-bearing amounts on deposit in excess of federally					7,800,000
Carrying value of asset group					1,385,000	$ 2,307,000
Impairment charges on long lived assets						13,400,000
Asset impairment charges					0
Amortization expense related to intangible assets					$ 983,000	1,768,000	$ 2,270,000
Impairment loss						13,981,000
Percentage of discount derived from capital asset pricing model					17.00%
Fair value of goodwill					$ 5,700,000
Goodwill					14,097,000	14,198,000	27,263,000
Allocation of goodwill to asset held for sale					394,000
Medical Device Excise tax included in the cost of revenue					491,000
Long term warranty obligations					0	2,000	5,000
Advertising expense					955,000	950,000	882,000
Goodwill and long-lived asset impairment				$ 27,400,000		27,443,000
Therapy [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Carrying value of asset group				36,800,000
Undiscounted cash flows over carrying value of assets				2,800,000
Impairment charges on long lived assets				13,400,000
Amortization expense related to intangible assets					$ 252,000	1,213,000	1,739,000
Impairment loss				$ 14,000,000		13,981,000
Percentage of fair value of each reporting unit					126.00%
Goodwill					$ 5,735,000	5,735,000	19,600,000
Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Amortization expense related to intangible assets					$ 696,000	532,000	515,000
Percentage of fair value of each reporting unit					816.00%
Goodwill					$ 8,362,000	8,463,000	$ 7,663,000
VuComp M-Vu Breast Density Product [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets		8 years 9 months
Business acquisition paid in cash	$ 1,700,000	$ 1,700,000				$ 1,700,000
Goodwill		$ 800,000			800,000
VuComp M-Vu CAD [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Business acquisition paid in cash			$ 6,000		$ 6,000
VuComp M-Vu CAD [Member] | Detection [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Goodwill			$ 293,000
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets					5 years
Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful lives of Long-lived assets					15 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Balance at beginning of period	$ 236	$ 203	$ 73
Additions charged to costs and expenses	177	383	167
Reductions	(241)	(350)	(37)
Balance at end of period	$ 172	$ 236	$ 203

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Schedule of Current Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Raw materials	$ 2,503	$ 2,900
Work in process	75	154
Finished Goods	1,149	1,261
Inventory	$ 3,727	$ 4,315

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2016
Minimum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Minimum [Member] | Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	3 years
Maximum [Member] | Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years
Maximum [Member] | Marketing Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Estimated life	5 years

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Gross Carrying Amount
Gross Carrying Amount	$ 10,701	$ 15,170
Accumulated Amortization
Accumulated Amortization	7,518	10,896
Total amortizable intangible assets, net	3,183	4,274
Patent and Licenses [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 583	579
Weighted average useful life	5 years
Accumulated Amortization
Accumulated Amortization	$ 477	451
Technology [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 9,567	14,075
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 6,754	9,996
Customer Relationships [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 292	268
Weighted average useful life	7 years
Accumulated Amortization
Accumulated Amortization	$ 28	201
Tradename [Member]
Gross Carrying Amount
Gross Carrying Amount	$ 259	248
Weighted average useful life	10 years
Accumulated Amortization
Accumulated Amortization	$ 259	$ 248

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Schedule of Expected Amortization Expense (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
2,017	$ 574
2,018	511
2,019	499
2,020	370
2,021	311
Thereafter	918
Total amortizable intangible assets, net	$ 3,183	$ 4,274

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Roll Forward of Goodwill Activity by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Goodwill [Line Items]
Sale of MRI assets		$ (394)
Accumulated Goodwill		54,906		$ 47,937
Accumulated impairment		(40,809)		(26,828)
Goodwill Balance		14,097	$ 14,198	27,263
Acquisition measurement period adjustments			116
Impairment			(13,981)
DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost				6,154
VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost		293	800
Goodwill Balance		800
Detection [Member]
Goodwill [Line Items]
Sale of MRI assets		(394)
Accumulated Goodwill		699
Fair value allocation		7,663		7,663
Goodwill Balance		8,362	8,463	7,663
Detection [Member] | VuComp M-Vu Breast Density Product [Member]
Goodwill [Line Items]
Acquisition cost		293	800
Therapy [Member]
Goodwill [Line Items]
Accumulated Goodwill		6,270
Fair value allocation		13,446		13,446
Accumulated impairment		(13,981)
Goodwill Balance		$ 5,735	5,735	19,600
Acquisition measurement period adjustments			116
Impairment	$ (14,000)		$ (13,981)
Therapy [Member] | DermEbx and Radion [Member]
Goodwill [Line Items]
Acquisition cost				$ 6,154

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Roll Forward of Warranty Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Beginning accrual balance	$ 19	$ 14	$ 25
Warranty provision	47	54	58
Usage	(55)	(49)	(69)
Ending accrual balance	$ 11	$ 19	$ 14

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Net loss available to common shareholders	$ (3,316)	$ (2,675)	$ (1,575)	$ (2,533)	$ (2,402)	$ (402)	$ (27,786)	$ (1,857)	$ (10,099)	$ (32,447)	$ (1,009)
Basic shares used in the calculation of earnings per share									15,932	15,686	14,096
Effect of dilutive securities:
Diluted shares used in the calculation of earnings per share									15,932	15,686	14,096
Basic									$ (0.63)	$ (2.07)	$ (0.07)
Diluted									$ (0.63)	$ (2.07)	$ (0.07)
Stock Options [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements									0	0	0
Restricted Stock [Member]
Effect of dilutive securities:
Incremental common shares attributable to share-based payment arrangements									0	0	0

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,936,746	2,088,394	1,727,204
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	1,425,348	1,571,998	1,417,887
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock options, warrants and restricted stock	511,398	516,396	309,317

Summary of Significant Accoun39

Summary of Significant Accounting Policies - Assets which are Measured at Fair Value on a Recurring Basis (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Assets
Money market accounts	$ 6,622	$ 13,577
Total Assets	6,622	13,577
Money Market Accounts [Member]
Assets
Money market accounts	6,622	13,577
Total Assets	6,622	13,577
Level 1 [Member]
Assets
Money market accounts	6,622	13,577
Total Assets	6,622	13,577
Level 1 [Member] | Money Market Accounts [Member]
Assets
Money market accounts	6,622	13,577
Total Assets	$ 6,622	$ 13,577

Acquisitions - Acquisition of V

Acquisitions - Acquisition of VuComp Cancer Detection Portfolio - Additional Information (Detail) - USD ($)	Jan. 13, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 14,097,000	$ 14,198,000	$ 27,263,000
Detection [Member]
Business Acquisition [Line Items]
Goodwill		8,362,000	$ 8,463,000	$ 7,663,000
MVu Breast Density [Member]
Business Acquisition [Line Items]
Gain on litigation settlement	$ 249,000
MVu Breast Density [Member] | Detection [Member]
Business Acquisition [Line Items]
Revenue from acquisition		200,000
VuComp Cancer Detection Portfolio [Member]
Business Acquisition [Line Items]
Goodwill	$ 293,000	$ 293,000
Goodwill amortization expense useful life		15 years

Acquisitions - Allocation of Pu

Acquisitions - Allocation of Purchase Price Based on Estimated Fair Values of Assets Acquired and liabilities Assumed (Detail) - USD ($) $ in Thousands	Jan. 13, 2016	Apr. 29, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill			$ 14,097	$ 14,198	$ 27,263
Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life			5 years
Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life			15 years
MVu Breast Density [Member]
Business Acquisition [Line Items]
Cash	$ 6
Acquisition litigation settlement	249
Purchase price	255
VuComp Cancer Detection Portfolio [Member]
Business Acquisition [Line Items]
Current assets	84
Property and equipment	65
Identifiable intangible assets	699
Goodwill	293		$ 293
Current liabilities	(280)
Long-term liabilities	(606)
Purchase price	$ 255
Property and equipment, Estimated amortizable life	3 years
VuComp Cancer Detection Portfolio [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	1 year
VuComp Cancer Detection Portfolio [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated amortizable life	10 years
VuComp M-Vu Breast Density Product [Member]
Business Acquisition [Line Items]
Developed Technology		$ 900
Goodwill		800	$ 800
Purchase price		$ 1,700
Estimated amortizable life		8 years 9 months

Acquisitions - Acquisition of42

Acquisitions - Acquisition of VuComp M-Vu Breast Density Product - Additional Information (Detail) - VuComp M-Vu Breast Density Product [Member] - USD ($)	Apr. 30, 2015	Apr. 29, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Business acquisition paid in cash	$ 1,700,000	$ 1,700,000	$ 1,700,000
Estimated amortizable life		8 years 9 months

Asset and Liabilities Held for

Asset and Liabilities Held for Sale - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Jan. 31, 2017
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Allocation of goodwill to asset held for sale	$ 394,000
VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale and transfer of intangible assets	3,200,000
Allocation of goodwill to asset held for sale	394,000
Gain on sale and transfer of intangible assets	$ 2,500,000
Subsequent Event [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member] | Asset Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Holdback reserve related to sale and transfer of intangible assets		$ 350,000
Proceeds from sale and transfer of intangible assets		$ 2,900,000

Assets and Liabilities Held f44

Assets and Liabilities Held for Sale - Schedule of Assets and Liabilities Held for sale (Detail)	Dec. 31, 2016USD ($)
Assets Held for Sale
Allocated Goodwill	$ 394,000
Total	1,304,000
Liabilities Held for Sale
Total	832,000
Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | VersaVue Software and DynaCAD Product and Related Assets [Member]
Assets Held for Sale
Accounts Receivable	98,000
Inventory	2,000
Intangible assets	810,000
Allocated Goodwill	394,000
Total	1,304,000
Liabilities Held for Sale
Deferred Revenue	832,000
Total	$ 832,000

Financing Arrangements - Additi

Financing Arrangements - Additional Information (Detail) - USD ($)	Apr. 30, 2014	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2011
Financing Arrangements [Line Items]
Aggregate purchase price of warrants	$ 1,575,000
Common stock, shares issued	450,000		16,260,663	15,923,349
Cancellation of warrants to purchase number of additional shares of common stock					100,000
Repayment of debt				$ 11,250,000	$ 7,850,000
Payment of accrued and unpaid interest			$ 70,000	558,000	1,637,000
Loss on extinguishment of debt				$ (1,723,000)	(903,000)
Facility Agreement [Member]
Financing Arrangements [Line Items]
Debt instrument, maturity date		Dec. 29, 2016
Repayment of debt		$ 11,250,000
Payment of accrued and unpaid interest		162,000
Loss on extinguishment of debt		$ (1,700,000)
Warrant [Member]
Financing Arrangements [Line Items]
Number of common stock shares issued			550,000
Exercise price of warrants			$ 3.50
Revenue Purchase Agreement [Member]
Financing Arrangements [Line Items]
Interest on facility agreement			5.75%
Facility Agreement [Member]
Financing Arrangements [Line Items]
Interest on facility agreement			5.75%
Revenue Purchase Agreement [Member]
Financing Arrangements [Line Items]
Payment for termination of agreement	$ 4,100,000
Recorded loss in connection with termination agreement					$ 900,000
Deerfield Agreement [Member]
Financing Arrangements [Line Items]
Amount provided in funding to company						$ 15,000,000

Financing Arrangements - Intere

Financing Arrangements - Interest Expense in Consolidated Income Statement (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Interest Expense, Debt [Abstract]
Cash interest expense		$ 163
Non-cash amortization of debt discount		254
Amortization of debt costs		13
Amortization of settlement obligations	$ 82	146	$ 206
Interest expense capital lease	70	220
Capital lease - fair value amortization	(89)	(146)
Total interest expense	$ 63	$ 650	$ 2,640

Accrued Expenses - Accrued Expe

Accrued Expenses - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued salary and related expenses	$ 1,878	$ 1,765
Accrued accounts payable	2,269	1,518
Accrued professional fees	316	425
Accrued short term settlement costs	474	418
Other accrued expenses	48	52
Deferred rent	3	42
Accrued Expenses Total	$ 4,988	$ 4,220

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2016USD ($)Incentive_Planshares	Dec. 31, 2015shares	Dec. 31, 2014shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock option | Incentive_Plan	5
Available for future grants	1,482,947
Total unrecognized compensation costs | $	$ 3,800,000
Period of expected recognized over a weighted average	1 year 1 month 6 days
Dividends paid on common stock | $	$ 0
Number of option Granted	127,500	363,239	281,043
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	1 year
Performance Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option Granted	162,500
Maximum [Member] | Performance Based Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares available for granted	108,333
2002 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	100,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2002 Stock Option Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	6 months
2002 Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of options granted	5 years
2004 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	5 months
Period of expiration	10 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 months
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
Stock Repurchase Program, Number of Shares Authorized to be Repurchased	200,000
2005 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	120,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Percentage of options granted	100.00%
Period of options granted	3 years
Period of expiration	5 years
Number of percentage of stockholders	10.00%
Period of expiration for specific stockholders	5 years
Period of exercisable stock option granted	10 years
Vesting date of grant, First anniversaries	33.00%
Vesting date of grant, Second anniversaries	33.00%
Vesting date of grant, Third anniversaries	33.00%
Number of share options available for grant	0
2007 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,050,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Number of share options available for grant	57,260
Aggregate purchase of Company's common stock, maximum	160,000
Percentage of options granted	100.00%
2012 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,600,000
Percentage of stockholders exercise price	10.00%
Percentage of market Price for calculation of purchase price	110.00%
Number of share options available for grant	155,964
Aggregate purchase of Company's common stock, maximum	250,000
Percentage of options granted	100.00%
2016 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate purchase of Company's common stock	1,700,000
Number of share options available for grant	1,269,722
Aggregate purchase of Company's common stock, maximum	1,000,000
Percentage of options granted	100.00%
Number of share options available for grant | $	$ 100,000
2016 Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	1,000,000
2016 Stock Option Plan [Member] | Maximum [Member] | Non Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share options available for grant	50,000

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity for all Stock Option Plans (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning balance	1,571,998	1,417,887	1,334,955
Granted	127,500	363,239	281,043
Exercised	(75,583)	(79,472)	(162,528)
Forfeited	(198,567)	(129,656)	(35,583)
Ending balance	1,425,348	1,571,998	1,417,887
Weighted Average, Beginning Balance	$ 5.05	$ 4.34	$ 4.75
Granted	5.46	6.58	8.08
Exercised	2.62	4.60	4.36
Forfeited	6.19	7.38	13.62
Weighted Average, Ending Balance	$ 5.05	$ 5.05	$ 4.34
Weighted Average Remaining Contractual Term, Outstanding	6 years 1 month 6 days
Exercisable, Number of Shares	1,054,211	1,087,725	955,210
Exercisable, Weighted Average Exercise Price	$ 4.71	$ 4.33	$ 4.43
Weighted Average Remaining Contractual Term, Exercisable	5 years 2 months 12 days

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense Including Options and Restricted Stock by Category (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 2,307	$ 2,135	$ 1,318
Cost of Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	6	14	13
Engineering and Product Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	329	223	165
Marketing and Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	677	659	353
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Allocated share-based compensation expense	$ 1,295	$ 1,239	$ 787

Stockholders' Equity - Options

Stockholders' Equity - Options Granted under Company's Stock Incentive Plans, Valuation Assumptions and Fair Values (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price	$ 5.46	$ 6.58	$ 8.08
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average risk-free interest rate	0.98%	0.97%	0.85%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	3 years 6 months	3 years 6 months	3 years 6 months
Weighted average exercise price	$ 5.46	$ 6.58	$ 8.09
Weighted average fair value	$ 2.66	$ 3.17	$ 3.84
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	68.50%	60.50%	64.20%
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.30%	75.20%	69.40%

Stockholders' Equity - Summar52

Stockholders' Equity - Summary of Intrinsic Values of Options and Closing Market Price (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Stock options outstanding	$ 409	$ 1,910	$ 6,343
Stock options exercisable	409	1,610	4,624
Stock options exercised	$ 201	$ 317	$ 1,081
Stock price	$ 3.24	$ 5.17	$ 9.17

Stockholders' Equity - Summar53

Stockholders' Equity - Summary of Restricted Stock Activity for All Equity Incentive Plans (Detail) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning outstanding balance	516,396	309,317	216,250
Granted	345,778	352,666	180,500
Vested	(289,030)	(124,758)	(85,434)
Forfeited	(61,746)	(20,829)	(1,999)
Ending outstanding balance	511,398	516,396	309,317

Stockholders' Equity - Summar54

Stockholders' Equity - Summary of Intrinsic Values of Restricted Stock and Closing Market Price (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding, Stock price	$ 3.24	$ 5.17	$ 9.17
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding, Beginning of period	$ 1,657	$ 2,670	$ 2,836
Number of stock options outstanding, Vested	$ 936	$ 645	$ 783
Number of stock options outstanding, Stock price	$ 3.24	$ 5.17	$ 9.17

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Current provision (benefit):
Federal			$ (44)
State	$ 69	$ 95	118
Current provision (benefit), Total	69	95	74
Deferred provision:
Federal	6	(65)	65
State	1	(14)	14
Deferred provision, Total	7	(79)	79
Total	$ 76	$ 16	$ 153

Income Taxes - Summary of Effec

Income Taxes - Summary of Effective and the Federal Statutory Income Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Federal statutory rate	34.00%	34.00%	34.00%
State income taxes, net of federal benefit	2.80%	2.50%	5.50%
Net state impact of deferred rate change	0.20%	(0.10%)	13.00%
Stock compensation expense	(3.20%)	(10.70%)	(9.60%)
Tax amortization on goodwill	(0.10%)	0.20%	(9.00%)
Loss on warrant	0.00%	0.00%	71.60%
Other permanent differences	(0.40%)	(0.10%)	(1.10%)
Change in valuation allowance	(37.30%)	(26.60%)	(222.60%)
Tax credits	3.20%	0.90%	100.80%
Effective income tax	(0.80%)	0.10%	(17.40%)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets ( Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Inventory (Section 263A)	$ 418	$ 588
Inventory reserves	105	106
Receivable reserves	65	159
Other accruals	434	591
Deferred revenue	215	367
Accumulated depreciation/amortization	477	417
Stock options	2,558	2,529
Developed technology	3,594	3,554
Tax credits	3,090	2,765
NOL carryforward	40,865	36,706
Net deferred tax assets	51,821	47,782
Valuation allowance	(51,821)	$ (47,782)
Goodwill tax amortization	(7)
Deferred tax liability	$ (7)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Income Tax Expense [Line Items]
Goodwill	$ 14,097,000	$ 14,198,000	$ 27,263,000
Net operating loss carryforwards	111,700,000
Net operating losses	(9,970,000)	(30,079,000)	815,000
Operating losses carryforwards	13,800,000
Net operating losses	2,000,000
Future Income tax liabilities offset With operation loss carryforward	$ 3,100,000
Tax credit carryforward expiration year	2,036
Unrecognized tax benefits	$ 0	0
Interest or penalties related to uncertain tax positions	$ 0	0	$ 0
Company preceding tax years	3 years
Xoft Inc [Member]
Schedule Of Income Tax Expense [Line Items]
Net operating loss carryforwards	$ 35,300,000
Net operating losses	0	$ 0
Operating losses carryforwards	9,500,000
Net operating losses	473,000
Deferred tax assets	0
Asset Acquisition January 2016 [Member]
Schedule Of Income Tax Expense [Line Items]
Goodwill	$ 293,307
Goodwill amortization expense useful life	15 years
Effective income tax rate amortization on goodwill amount	$ 6,844
Minimum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2,019
Maximum [Member]
Schedule Of Income Tax Expense [Line Items]
Expiring date of net operating loss carryforward	2,036

Segment Reporting, Geographic59

Segment Reporting, Geographical Information and Major Customers - Additional Information (Detail)	3 Months Ended								12 Months Ended
	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2016USD ($)SegmentCustomer	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Schedule Of Geographical Information [Line Items]
Number of reporting segments | Segment									2
Total Export Sales	$ 6,928,000	$ 6,003,000	$ 7,369,000	$ 6,038,000	$ 7,609,000	$ 9,582,000	$ 11,143,000	$ 13,220,000	$ 26,338,000	$ 41,554,000	$ 43,924,000
Percentage of export sales to any single country									10.00%
Number of major customers | Customer									1
GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	1,300,000								$ 1,300,000
Oem [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	1,500,000								1,500,000
Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	600,000								600,000
Six Customers [Member]
Schedule Of Geographical Information [Line Items]
Outstanding receivables	2,100,000								2,100,000
Detection [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									17,133,000	19,243,000	18,604,000
Sales [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Total revenue									$ 3,900,000	$ 4,100,000	$ 4,100,000
Sales [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									15.00%	10.00%	9.00%
Sales [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									30.00%	25.00%	22.00%
Sales [Member] | Detection [Member] | Customer Concentration Risk [Member] | Five Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									47.00%	53.00%	53.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | GE Healthcare [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									23.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Oem [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									28.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									12.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Six Customers [Member]
Schedule Of Geographical Information [Line Items]
Percentage of receivables									40.00%
Foreign [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									$ 2,300,000	$ 2,300,000	$ 1,800,000
Percentage of export sales of total sale									9.00%	6.00%	4.00%
Outstanding receivables	$ 300,000				$ 500,000				$ 300,000	$ 500,000
Intersegment Eliminations [Member]
Schedule Of Geographical Information [Line Items]
Total Export Sales									$ 0

Segment Reporting, Geographic60

Segment Reporting, Geographical Information and Major Customers - Summary of Segment Revenues, Gross Profit, Segment Operating Income or Loss and Reconciliation of Segment Operating Income or Loss to GAAP Loss (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Segment revenues:
Total revenue	$ 6,928	$ 6,003	$ 7,369	$ 6,038	$ 7,609	$ 9,582	$ 11,143	$ 13,220	$ 26,338	$ 41,554	$ 43,924
Segment gross profit:
Segment gross profit	$ 4,529	$ 4,101	$ 5,702	$ 4,186	$ 5,289	$ 6,821	$ 7,878	$ 9,362	18,518	29,350	31,227
Segment operating income (loss):
Segment operating income (loss)									(2,058)	(21,172)	9,099
General, administrative, depreciation and amortization expense									(7,912)	(8,907)	(8,284)
Interest expense									(63)	(650)	(2,640)
Gain (loss) on fair value of warrant											1,835
Other income									10	21	37
Loss on debt extinguishment										(1,723)	(903)
Loss before income tax expense									(10,023)	(32,431)	(856)
Detection [Member]
Segment revenues:
Total revenue									17,133	19,243	18,604
Segment gross profit:
Segment gross profit									15,113	16,019	15,276
Segment operating income (loss):
Segment operating income (loss)									5,694	7,233	7,231
Therapy [Member]
Segment revenues:
Total revenue									9,205	22,311	25,320
Segment gross profit:
Segment gross profit									3,405	13,331	15,951
Segment operating income (loss):
Segment operating income (loss)									$ (7,752)	$ (28,405)	$ 1,868

Segment Reporting, Geographic61

Segment Reporting, Geographical Information and Major Customers - Summary of Segment Depreciation and Amortization Included in Segment Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	$ 1,322	$ 1,580	$ 1,256
Amortization	983	1,768	2,270
Detection [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	223	220	188
Amortization	696	532	515
Therapy [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Depreciation	970	1,142	844
Amortization	$ 252	$ 1,213	$ 1,739

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended		12 Months Ended
	Feb. 28, 2010USD ($)	Jul. 31, 2007USD ($)	Dec. 31, 2016USD ($)ft²Lease	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)LeaseContracts
Loss Contingencies [Line Items]
Lease obligations | Lease			3
Annual base rent			$ 89,000
Operating lease, annual rent, current			579,000
Operating lease, annual rent			2,237,000
Operating lease, annual rent, second year			738,000
Operating lease, annual rent, third year			746,000
Rent expense			745,000	$ 663,000	$ 643,000
Outstanding liability on equipment leases			0	$ 86,000
Total lease payments			86,000
Annual lease payments in 2017			89,000
Purchase obligations to suppliers for future product deliverables			300,000
Employer matching Contribution			400,000
Employer matching Contribution to be paid in next fiscal year			500,000
Minimum annual royalty payment			250,000
Fair value of patent license			$ 100,000
Patent license, Estimated Amortizable Life			4 years
Minimum royalty obligations			$ 400,000
Litigation and settlement obligation, Total			500,000
Estimated value of liability			400,000
DermEbx and Radion [Member]
Loss Contingencies [Line Items]
Number of equipment lease obligation | LeaseContracts					2
Assumed capital leases					$ 2,600,000
Liability recorded on capital leases					$ 2,500,000
Outstanding liability on equipment leases			100,000
Total lease payments			100,000
Annual lease payments in 2017			$ 76,000
Nashua [Member]
Loss Contingencies [Line Items]
Term of lease			5 years
Area of office space | ft²			11,000
Annual base rent			$ 184,518
San Jose California [Member]
Loss Contingencies [Line Items]
Operating lease, annual rent, current			295,140
Operating lease, annual rent			$ 540,588
Area of office, manufacturing and warehousing space | ft²			24,250
Operating lease, annual rent, second year			$ 558,120
Operating lease, annual rent, third year			$ 286,368
CADx Medical Systems Inc [Member]
Loss Contingencies [Line Items]
Tax re-assessment received		$ 6,800,000
Reduced tax re-assessment received	$ 703,000

Commitments and Contingencies63

Commitments and Contingencies - Future Minimum Rental Payments (Detail) $ in Thousands	Dec. 31, 2016USD ($)
Leases [Abstract]
2,017	$ 579
2,018	738
2,019	746
2,020	174
Total	$ 2,237

Commitments and Contingencies64

Commitments and Contingencies - Future Minimum Lease Payments under Non-cancelable Capital Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Leases [Abstract]
2,017	$ 89
Subtotal minimum lease obligation	89
Less interest	(3)
Total, net	86
Less current portion	(86)
Long term portion	$ 0	$ 86

Quarterly Financial Data - Quar

Quarterly Financial Data - Quarterly Financial Data (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Net sales	$ 6,928	$ 6,003	$ 7,369	$ 6,038	$ 7,609	$ 9,582	$ 11,143	$ 13,220	$ 26,338	$ 41,554	$ 43,924
Gross profit	4,529	4,101	5,702	4,186	5,289	6,821	7,878	9,362	18,518	29,350	31,227
Net loss	$ (3,316)	$ (2,675)	$ (1,575)	$ (2,533)	$ (2,402)	$ (402)	$ (27,786)	$ (1,857)	$ (10,099)	$ (32,447)	$ (1,009)
Income (loss) per share	$ (0.20)	$ (0.17)	$ (0.10)	$ (0.16)	$ (0.15)	$ (0.03)	$ (1.77)	$ (0.12)
Weighted average number of shares outstanding	16,214	15,957	15,904	15,826	15,733	15,725	15,679	15,605

Quarterly Financial Data - Qu66

Quarterly Financial Data - Quarterly Financial Data (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Goodwill and long-lived asset impairment	$ 27,400	$ 27,443